Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection

Journal of Virological Methods

Volumn 156, Issue 1-2, 2009, Pages 37-43

  Di Lullo, Giulia ^a   Soprana, Elisa ^a   Panigada, Maddalena ^a,b   Palini, Alessio ^a   Erfle, Volker ^c   Staib, Caroline ^c   Sutter, Gerd ^c   Siccardi, Antonio G ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fluorescent proteins; Host range selection; K1Lgfp; Marker gene swapping; Recombinant MVA

Indexed keywords

GREEN FLUORESCENT PROTEIN; RED FLUORESCENT PROTEIN;

ARTICLE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; HOST RANGE; HOST SELECTION; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; CELL LINE; CRICETINAE; DEFECTIVE VIRUSES; DNA, RECOMBINANT; DNA, VIRAL; FLUORESCENT DYES; GENES, REPORTER; GENES, VIRAL; GENETIC ENGINEERING; GENETIC VECTORS; MICROSCOPY, FLUORESCENCE; PLASMIDS; RABBITS; SPECIES SPECIFICITY; TRANSFECTION; TRANSGENES; VACCINIA VIRUS;

MAMMALIA; VACCINIA VIRUS ANKARA;

EID: 59749095846     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.10.026     Document Type: Article

References (27)

1. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 20 (2002) 1949-1955
2. Anand S., Batista F.D., Tkach T., Efremov D.G., and Burrone O.R. Multiple transcripts of the murine immunoglobulin epsilon membrane locus are generated by alternative splicing and differential usage of two polyadenylation sites. Mol. Immunol. 34 (1997) 175-183
3. Antoine G., Scheiflinger F., Dorner F., and Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244 2 (1998) 365-396 Erratum in: Virology 350(2), 501-502 (2006)
4. Barouch D.H., Santra S., Kuroda M.J., Schmitz J.E., Plishka R., Buckler-White A., Gaitan A.E., Zin R., Nam J.H., Wyatt L.S., Lifton M.A., Nickerson C.E., Moss B., Montefiori D.C., Hirsch V.M., and Letvin N.L. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75 (2001) 5151-5158
5. Bejon P., Ogada E., Mwangi T., Milligan P., Lang T., Fegan G., Gilbert S.C., Peshu N., Marsh K., and Hill A.V. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS One 2 (2007) e707
6. Carroll M.W., Overwijk W.W., Chamberlain R.S., Rosenberg S.A., Moss B., and Restifo N.P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15 (1997) 387-394
7. Carroll M.W., and Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238 (1997) 198-211
8. Cosma A., Nagaraj R., Bühler S., Hinkula J., Busch D.H., Sutter G., Goebel F.D., and Erfle V. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22 (2003) 21-29
9. Drexler I., Heller K., Wahren B., Erfle V., and Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79 (1998) 347-352
10. Drexler I., Antunes E., Schmitz M., Wölfel T., Huber C., Erfle V., Rieber P., Theobald M., and Sutter G. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res. 59 (1999) 4955-4963
11. Hirsch V.M., Fuerst T.R., Sutter G., Carroll M.W., Yang L.C., Goldstein S., Piatak Jr. M., Elkins W.R., Alvord W.G., Montefiori D.C., Moss B., and Lifson J.D. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70 (1996) 3741-3752
12. Hornemann S., Harlin O., Staib C., Kisling S., Erfle V., Kaspers B., Häcker G., and Sutter G. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J. Virol. 77 (2003) 8394-8407
13. Jaoko W., Nakwagala F.N., Anzala O., Manyonyi G.O., Birungi J., Nanvubya A., Bashir F., Bhatt K., Ogutu H., Wakasiaka S., Matu L., Waruingi W., Odada J., Oyaro M., Indangasi J., Ndinya-Achola J., Konde C., Mugisha E., Fast P., Schmidt C., Gilmour J., Tarragona T., Smith C., Barin B., Dally L., Johnson B., Muluubya A., Nielsen L., Hayes P., Boaz M., Hughes P., Hanke T., McMichael A., Bwayo J., and Kaleebu P. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in human in East Africa. Vaccine 26 (2008) 2788-2795
14. Li E., Pedraza A., Bestagno M., Mancardi S., Sanchez R., and Burrone O. Mammalian cell expression of dimeric small immune proteins (SIP). Protein Eng. 10 (1997) 731-736
15. Mayr A., Hochstein-Mintzel V., and Stickl H. Abstammung Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3 (1975) 6-14
16. Mayr A., and Danner K. Bedeutung von Tierpochen fiir den Menschen nach Aufhebung der Pflichtimpfung gegen Pocken. Berliner und Mi2nchener tieri-rztliche Wochenschrift 92 (1979) 251-256
17. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., Vuola J.M., Blanchard T.J., Gothard P., Watkins K., Hannan C.M., Everaere S., Brown K., Kester K.E., Cummings J., Williams J., Heppner D.G., Pathan A., Flanagan K., Arulanantham N., Roberts M.T., Roy M., Smith G.L., Schneider J., Peto T., Sinden R.E., Gilbert S.C., and Hill A.V. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9 (2003) 729-735
18. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72 (1991) 1031-1038
19. Ramirez J.C., Gherardi M.M., Rodriguez D., and Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol. 74 (2000) 7651-7655
20. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., Becker M., Sinden R., Smith G.L., and Hill A.V. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4 (1998) 397-402
21. Staib C., Drexler I., Ohlmann M., Wintersperger S., Erfle V., and Sutter G. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 28 (2000) pp. 1137-1142, 1144-1136, 1148
22. Staib C., Lowel M., Erfle V., and Sutter G. Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques 34 (2003) pp. 694-696, 698, 700
23. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U.S.A. 89 (1992) 10847-10851
24. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., and Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12 (1994) 1032-1040
25. Sutter G., Ramsey-Ewing A., Rosales R., and Moss B. Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J. Virol. 68 (1994) 4109-4116
26. Weidinger G., Ohlmann M., Schlereth B., Sutter G., and Niewiesk S. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model. Vaccine 19 (2001) 2764-2768
27. Wyatt L.S., Shors S.T., Murphy B.R., and Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14 (1996) 1451-1458